Anti-PD-1 antibody

CStone Pharmaceuticals announced Wednesday that it has entered into a strategic partnership and exclusive licensing agreement with Shenyang Sunshine Pharmaceutical, a subsidiary of 3SBio Inc., for anti-PD-1 antibody Nofazinlimab in mainland China.

FAST NEWS: CStone licenses PD-1 cancer drug to 3SBio for China

The latest: CStone Pharmaceuticals (2616.HK) announced Wednesday that it has exclusively licensed Shenyang Sunshine Pharmaceutical, a subsidiary of 3SBio Inc. (1530.HK), to develop, register, manufacture and commercialize its anti-PD-1 antibody Nofazinlimab…
2616.HK

Recent Articles

RELATED ARTICLES

  1. CSPC Pharma weighs up diet drug for bigger bottom line
    CSPC Pharma weighs up diet drug for bigger bottom line
    1093.HK
  2. Hutchmed scores U.S. success with cancer drug, but profits still dip
    HCM.US 0013.HK
  3. CSPC Pharma taps R&D superstar in quest for new breakout drugs
    1093.HK
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva